Back to all Current clinical trials
Back to all Current clinical trials
A potential new treatment for Eosinophilic Esophagitis (EoE)
This is a 24-week randomized, double-blind, placebo-controlled Phase 2 clinical study with a 28-week extension to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of 3 dose levels of solrikitug versus placebo on top of standard of care in adult participants with EoE.
What you need to know
Who can take part?
To participate you must:
- Be aged 18-75
- Weigh 40kg or more
- Have a confirmed diagnosis of Eosinophilic Esophagitis
- Have difficultly swallowing
- Have a stable diet for at least 4 weeks
- Be on a stable dose of your current treatment
- Have blood & urine test results within standard ranges
- Not be pregnant or planning pregnancy
- Not have a current or recent infection
- Not be undergoing Immunosuppression treatment
- Not have a previous cancer diagnosis
- Not have failed treatment with dupilumab
- Not have strictures
- Certain medications may make you ineligible to participate
What is involved for me?
- Medical history and collection of demographic information
- Vital signs
- Electrocardiogram
- Physical exam
- Blood and urine tests
- Pregnancy tests for women with childbearing potential
- Endoscopy with esophagus tissue biopsy
- Daily diary completion
- Questionnaires
- Treatment by sub-cutaneous injections
